

# David T Teachey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/470673/publications.pdf>

Version: 2024-02-01

200  
papers

20,818  
citations

26610

56  
h-index

10441

139  
g-index

271  
all docs

271  
docs citations

271  
times ranked

21052  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hodgkin lymphoma in an individual with <i>TREX1</i> -mediated Aicardi Goutières syndrome. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29322.	0.8	1
2	Transcriptome and unique cytokine microenvironment of Castleman disease. <i>Modern Pathology</i> , 2022, 35, 451-461.	2.9	10
3	Lymphoproliferative disorders. , 2022, , 377-390.		0
4	Taking a BiTE Out of CAR-T Cell Efficacy. <i>Journal of Clinical Oncology</i> , 2022, 40, 921-923.	0.8	1
5	Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia. <i>Haematologica</i> , 2022, 107, 1746-1757.	1.7	14
6	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. <i>Cancer</i> , 2022, 128, 1863-1870.	2.0	12
7	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	0.8	45
8	Kikuchi-Fujimoto disease is mediated by an aberrant type I interferon response. <i>Modern Pathology</i> , 2022, 35, 462-469.	2.9	4
9	Potential Role of IFN $\gamma$ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. <i>Blood Cancer Discovery</i> , 2022, 3, 90-94.	2.6	23
10	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1499-1507.	3.3	6
11	Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, , .	1.2	6
12	Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. <i>Blood</i> , 2022, 140, 619-629.	0.6	45
13	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. <i>Nature Communications</i> , 2022, 13, 2801.	5.8	25
14	Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10001-10001.	0.8	15
15	Impact of socioeconomic status on survival after CD19 CART therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7013-7013.	0.8	0
16	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. <i>Clinical Cancer Research</i> , 2022, 28, 3804-3813.	3.2	17
17	Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies. <i>Clinical Cancer Research</i> , 2022, 28, 3940-3949.	3.2	4
18	Please eat me! Targeting CD47 and CD38 in T-ALL. <i>Blood</i> , 2022, 140, 6-8.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Human Adenovirus 7-Associated Hemophagocytic Lymphohistiocytosis-like Illness: Clinical and Virological Characteristics in a Cluster of Five Pediatric Cases. <i>Clinical Infectious Diseases</i> , 2021, 73, e1532-e1538.	2.9	12
20	Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. <i>Blood</i> , 2021, 137, 2463-2480.	0.6	35
21	Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19). <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 669-673.	0.6	45
22	Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 168-177.	0.6	35
23	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. <i>Blood Advances</i> , 2021, 5, 593-601.	2.5	28
24	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2021, 2, 284-299.	5.7	70
25	Xenograft models for pediatric cancer therapies. <i>Faculty Reviews</i> , 2021, 10, 11.	1.7	2
26	Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29026.	0.8	11
27	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 920-930.	0.8	110
28	Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19. <i>Science Immunology</i> , 2021, 6, .	5.6	152
29	Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis. <i>Journal of Clinical Immunology</i> , 2021, 41, 1213-1218.	2.0	10
30	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10002-10002.	0.8	0
31	Prognostic Impact of CNS-2 status in T-ALL: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10003-10003.	0.8	0
32	Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29123.	0.8	15
33	Skewed Cytokine Responses Rather Than the Magnitude of the Cytokine Storm May Drive Cardiac Dysfunction in Multisystem Inflammatory Syndrome in Children. <i>Journal of the American Heart Association</i> , 2021, 10, e021428.	1.6	18
34	Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 677-678.	12.5	9
35	Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 3044-3055.	0.8	94
36	Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva. <i>Bone</i> , 2021, 150, 116016.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Novel Approaches to T-Cell ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S95-S98.	0.2	0
38	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
39	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-L) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3487-3487.	0.6	1
40	Treatment Resistance in ETP-ALL Is Associated with Progenitor-like Arrest State. <i>Blood</i> , 2021, 138, 618-618.	0.6	0
41	Non-Classical Monocyte Abundance Is an Independent Adverse Risk Factor for Relapse in Pediatric B-ALL. <i>Blood</i> , 2021, 138, 1316-1316.	0.6	0
42	The Role of PF4 Antibodies in Pediatric Sars-Cov-2 Infections. <i>Blood</i> , 2021, 138, 1004-1004.	0.6	0
43	Development of Proteolytic Targeting Chimeras to Target Lck in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 867-867.	0.6	2
44	Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. <i>Nature Communications</i> , 2021, 12, 7222.	5.8	41
45	Childhood Leukemia. , 2020, , 1748-1764.e4.		6
46	Partially CD3+-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 493-501.	2.0	3
47	Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1029-1042.	1.3	8
48	PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1809-1821.	1.9	6
49	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. <i>Blood Advances</i> , 2020, 4, 5174-5183.	2.5	30
50	Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28693.	0.8	37
51	Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. <i>Blood Advances</i> , 2020, 4, 6051-6063.	2.5	105
52	Distinguishing Multisystem Inflammatory Syndrome in Children From Kawasaki Disease and Benign Inflammatory Illnesses in the SARS-CoV-2 Pandemic. <i>Pediatric Emergency Care</i> , 2020, 36, 554-558.	0.5	20
53	Increased mTOR activation in idiopathic multicentric Castleman disease. <i>Blood</i> , 2020, 135, 1673-1684.	0.6	52
54	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia. <i>Molecular Cancer Research</i> , 2020, 18, 1153-1165.	1.5	20

#	ARTICLE	IF	CITATIONS
55	Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>Anticancer Research</i> , 2020, 40, 3147-3153.	0.5	13
56	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3070.	0.8	42
57	Harnessing immunotherapy for pediatric T-cell malignancies. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 361-371.	1.3	12
58	Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S39.	2.0	12
59	Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis*. <i>Critical Care Medicine</i> , 2020, 48, 344-352.	0.4	20
60	How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. <i>Blood</i> , 2020, 135, 159-166.	0.6	104
61	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
62	Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. <i>Journal of Clinical Investigation</i> , 2020, 130, 863-876.	3.9	36
63	Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. <i>Journal of Clinical Investigation</i> , 2020, 130, 5967-5975.	3.9	319
64	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. <i>Blood</i> , 2020, 136, 20-21.	0.6	5
65	Convalescent Plasma for COVID-19: An Old Therapy for a Novel Pathogen. , 2020, 17, .		2
66	Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. <i>Therapeutics and Clinical Risk Management</i> , 2020, 16, 705-714.	0.9	40
67	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 81-112.	2.3	102
68	Bringing Immunotherapy to the Front Line in Childhood Leukemia. , 2020, 17, .		0
69	Outcomes for Children With SR-ALL: More Is Not Always Better. , 2020, 17, .		0
70	Germline Predisposition to Childhood Leukemia: T-ALL Risk Variants Uncovered in GWAS. , 2020, 17, .		0
71	Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor. <i>Blood</i> , 2020, 136, 18-20.	0.6	2
72	CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. <i>PLoS ONE</i> , 2019, 14, e0220026.	1.1	16

#	ARTICLE	IF	CITATIONS
73	Cellular therapy: Immune-related complications. <i>Immunological Reviews</i> , 2019, 290, 114-126.	2.8	55
74	Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 813-822.	1.3	221
75	Excellent outcomes for patients with B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses. <i>Lancet Haematology</i> , 2019, 6, e172-e173.	2.2	0
76	Development of hemolytic paroxysmal nocturnal hemoglobinuria without graft loss following hematopoietic stem cell transplantation for acquired aplastic anemia. <i>Pediatric Transplantation</i> , 2019, 23, e13393.	0.5	1
77	Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. <i>Lancet Oncology</i> , 2019, 20, e142-e154.	5.1	149
78	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). <i>Clinical Cancer Research</i> , 2019, 25, 3229-3238.	3.2	61
79	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. <i>Oncogene</i> , 2019, 38, 2241-2262.	2.6	29
80	From Aminopterin to Tisagenlecleucel: Childhood Acute Lymphoblastic Leukemia at the Forefront of Cancer Breakthroughs. , 2019, 16, .		0
81	Popping the Bubble: Promising Results From a Phase I-II Lentiviral Gene Therapy Trial for X-SCID. , 2019, 16, .		0
82	A Novel Immunotherapy for T-ALL. , 2019, 16, .		0
83	Venetoclax for Hypodiploid ALL: Novel Therapy for Bad Biology. , 2019, 16, .		0
84	Hematopoietic Stem Cell Transplantation: Not Always a Panacea for Leukemia Patients With Unfavorable Outcome. , 2019, 16, .		0
85	JAKing Up Targeted Therapy for Ph-like Acute Lymphoblastic Leukemia. , 2019, 16, .		0
86	Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10033-10033.	0.8	0
87	Hypofibrinogenemia Is Associated With Poor Outcome and Secondary Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in Pediatric Severe Sepsis*. <i>Pediatric Critical Care Medicine</i> , 2018, 19, 397-405.	0.2	21
88	Gene Therapy in Patients with Transfusion-Dependent $\beta^2$ -Thalassemia. <i>New England Journal of Medicine</i> , 2018, 378, 1479-1493.	13.9	525
89	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 218-218.	12.5	93
90	Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors. <i>Cancer Cell</i> , 2018, 33, 274-291.e8.	7.7	58

#	ARTICLE	IF	CITATIONS
91	Immunotherapy for ALL takes the world by storm. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 69-70.	12.5	25
92	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 995-999.	0.6	170
93	MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. <i>Haematologica</i> , 2018, 103, 830-839.	1.7	35
94	Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases. <i>Bone</i> , 2018, 109, 276-280.	1.4	34
95	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 3094-3114.	4.2	37
96	Neurotoxicity after CTL019 in a pediatric and young adult cohort. <i>Annals of Neurology</i> , 2018, 84, 537-546.	2.8	82
97	Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 959-971.	1.1	19
98	Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 556-556.	0.6	106
99	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2018, 132, 1000-1000.	0.6	2
100	A New Standard of Care for Children and Young Adults With T-cell Acute Lymphoblastic Leukemia. , 2018, 15, .		0
101	Novel Insights From Comprehensive Genomic Profiling of T Cell Acute Lymphoblastic Leukemia. , 2018, 15, .		0
102	Remission: More Than Meets the Eye. , 2018, 15, .		2
103	The Importance of Genomic Testing in Children With Complex Autoimmune Cytopenias: Precision Medicine Is Not Just for Cancer. , 2018, 15, .		0
104	Spare the Spleen in ALPS: It Is Not an Expendable Vestigial Organ. <i>Blood</i> , 2018, 132, 2435-2435.	0.6	0
105	Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 913-913.	0.6	0
106	PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL. <i>Blood</i> , 2018, 132, 889-889.	0.6	0
107	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 177-187.	0.6	138
108	Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. <i>Cytotherapy</i> , 2017, 19, 867-880.	0.3	116



#	ARTICLE	IF	CITATIONS
109	Behcet Disease Initially Presenting as Deep Venous Thrombosis: A Case Report. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 410-412.	0.3	4
110	Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. <i>Critical Care Medicine</i> , 2017, 45, e124-e131.	0.4	357
111	A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). <i>British Journal of Haematology</i> , 2017, 177, 467-474.	1.2	32
112	Severe Muhaa€“Habermanna€“Like Ulceronecrotic Skin Disease in Taa€“Cell Acute Lymphoblastic Leukemia Responsive to Basiliximab and Stem Cell Transplant. <i>Pediatric Dermatology</i> , 2017, 34, e265-e270.	0.5	6
113	Autoimmune lymphoproliferative syndrome: more than a FAScinating disease. <i>F1000Research</i> , 2017, 6, 1928.	0.8	76
114	The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 103-103.	0.8	80
115	Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10507-10507.	0.8	16
116	Successful Treatment of Recurrent Autoimmune Cytopenias in the Context of Sinus Histiocytosis With Massive Lymphadenopathy Using Sirolimus. <i>Pediatric Blood and Cancer</i> , 2016, 63, 358-360.	0.8	18
117	T-cell acute lymphoblastic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 580-588.	0.9	176
118	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. <i>Journal of Immunological Methods</i> , 2016, 434, 1-8.	0.6	150
119	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2016, 6, 664-679.	7.7	811
120	Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children. <i>Paediatric Drugs</i> , 2016, 18, 261-272.	1.3	18
121	Lymphoproliferative Disorders. , 2016, , 334-347.		0
122	Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1736-1737.	2.0	19
123	Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. <i>Blood</i> , 2016, 127, 17-28.	0.6	165
124	The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. <i>Expert Review of Hematology</i> , 2016, 9, 873-889.	1.0	21
125	Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia. <i>Cancer Research</i> , 2016, 76, 2766-2777.	0.4	16
126	Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. <i>Pediatric Blood and Cancer</i> , 2016, 63, 156-159.	0.8	23



#	ARTICLE	IF	CITATIONS
127	Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. <i>Journal of Clinical Oncology</i> , 2016, 34, 3007-3007.	0.8	17
128	Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. <i>Journal of Clinical Oncology</i> , 2016, 34, 3011-3011.	0.8	98
129	MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. <i>Blood</i> , 2015, 126, 2202-2212.	0.6	88
130	Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. <i>Blood</i> , 2015, 126, 629-639.	0.6	110
131	CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 4017-4023.	0.6	598
132	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 1759-1767.	0.6	189
133	Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 1334-1334.	0.6	5
134	Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. <i>Blood</i> , 2015, 126, 3769-3769.	0.6	40
135	Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL. <i>Blood</i> , 2015, 126, 683-683.	0.6	22
136	Temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): A Children's Oncology Group study. <i>Journal of Clinical Oncology</i> , 2015, 33, 10029-10029.	0.8	2
137	Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. <i>Frontiers in Oncology</i> , 2014, 4, 108.	1.3	92
138	Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 119-122.	1.0	624
139	Toxicity management for patients receiving novel T-cell engaging therapies. <i>Current Opinion in Pediatrics</i> , 2014, 26, 43-49.	1.0	130
140	Loss of TBL1XR1 Disrupts Glucocorticoid Receptor Recruitment to Chromatin and Results in Glucocorticoid Resistance in a B-Lymphoblastic Leukemia Model. <i>Journal of Biological Chemistry</i> , 2014, 289, 20502-20515.	1.6	52
141	Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1507-1517.	13.9	4,444
142	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. <i>Blood</i> , 2014, 123, 2017-2025.	0.6	109
143	Targeting cytokines in ALPS: it's Fashionable. <i>Blood</i> , 2014, 123, 1116-1118.	0.6	3
144	Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL. <i>Blood</i> , 2014, 124, 1983-1983.	0.6	6

#	ARTICLE	IF	CITATIONS
145	The CXCR4/CXCL12 Axis Mediates Chemotaxis, Survival, and Chemoresistance in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3629-3629.	0.6	6
146	T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL. <i>Blood</i> , 2014, 124, 380-380.	0.6	14
147	Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling. <i>Blood</i> , 2014, 124, 969-969.	0.6	0
148	Immunologic Recovery in Children after Alternative Donor Allogeneic Transplantation for Hematologic Malignancies: Comparison of Recipients of Partially T Cell-Depleted Peripheral Blood Stem Cells and Umbilical Cord Blood. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1581-1589.	2.0	29
149	Diagnosis and Management of Autoimmune Cytopenias in Childhood. <i>Pediatric Clinics of North America</i> , 2013, 60, 1489-1511.	0.9	74
150	Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2013, 368, 1509-1518.	13.9	3,021
151	Predicting relapse risk in childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2013, 162, 606-620.	1.2	89
152	Treatment of Epstein-Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemotherapy regimens. <i>British Journal of Haematology</i> , 2013, 162, 376-382.	1.2	191
153	Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. <i>Blood</i> , 2013, 121, 5154-5157.	0.6	524
154	In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 2672-2672.	0.6	5
155	Targeting mTOR Signaling Leads To Complete and Durable Responses In Children With Multi-Lineage Autoimmune Cytopenias, Including ALPS, SLE, Evans and CVID. <i>Blood</i> , 2013, 122, 330-330.	0.6	2
156	T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL. <i>Blood</i> , 2013, 122, 67-67.	0.6	17
157	PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 1669-1669.	0.6	7
158	Deletions In TBL1XR1 Results In Glucocorticoid Resistance By Decreasing Glucocorticoid Signaling In Childhood B-Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 602-602.	0.6	1
159	New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. <i>Current Opinion in Pediatrics</i> , 2012, 24, 1-8.	1.0	94
160	Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study. <i>Clinical Cancer Research</i> , 2012, 18, 6058-6064.	3.2	110
161	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 3510-3518.	0.6	263
162	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 153-166.	7.7	621

#	ARTICLE	IF	CITATIONS
163	Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies. Paediatric Drugs, 2012, 14, 299-316.	1.3	31
164	Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies. Paediatric Drugs, 2012, 14, 299-316.	1.3	86
165	In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology, 2012, 30, 9506-9506.	0.8	0
166	CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).. Blood, 2012, 120, 2604-2604.	0.6	6
167	Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood, 2011, 118, e112-e117.	0.6	49
168	Statins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis. British Journal of Haematology, 2011, 155, 403-407.	1.2	13
169	Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice. Pediatric Blood and Cancer, 2011, 57, 1239-1243.	0.8	3
170	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. Blood, 2011, 118, 837-837.	0.6	1
171	Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL). Blood, 2011, 118, 249-249.	0.6	1
172	Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood, 2010, 115, 2142-2145.	0.6	84
173	Somatic ALPS: a FAScinating condition. Blood, 2010, 115, 5125-5126.	0.6	6
174	Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). British Journal of Haematology, 2010, 148, 205-216.	1.2	115
175	Cutting Edge: Lymphoproliferation Caused by Fas Deficiency Is Dependent on the Transcription Factor Eomesodermin. Journal of Immunology, 2010, 185, 7151-7155.	0.4	16
176	Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood, 2010, 116, e35-e40.	0.6	405
177	Targeting mTOR Signaling Is An Effective Treatment Strategy for IKAROS and JAK Kinase Mutated Acute Lymphoblastic Leukemia. Blood, 2010, 116, 3251-3251.	0.6	0
178	Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant. Pediatric Blood and Cancer, 2009, 53, 1114-1116.	0.8	22
179	Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. British Journal of Haematology, 2009, 145, 101-106.	1.2	151
180	Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. British Journal of Haematology, 2009, 145, 569-580.	1.2	106

#	ARTICLE	IF	CITATIONS
181	Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. <i>Molecular Therapy</i> , 2009, 17, 1453-1464.	3.7	988
182	Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. <i>Immunologic Research</i> , 2008, 42, 84-105.	1.3	35
183	Saddle Pulmonary Embolism as a Complication of Vasectomy. <i>Urology</i> , 2008, 71, 351.e5-351.e6.	0.5	3
184	Targeting Notch signaling in autoimmune and lymphoproliferative disease. <i>Blood</i> , 2008, 111, 705-714.	0.6	68
185	mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. <i>Blood</i> , 2008, 112, 2020-2023.	0.6	117
186	Targeting HMG-CoA Reductase in Acute Lymphoblastic Leukemia (ALL): Statins Inhibit Proliferation and Induce Apoptosis in ALL Cells. <i>Blood</i> , 2008, 112, 2927-2927.	0.6	4
187	Thymic Stromal-Derived Lymphopoietin Induces Proliferation of Pre-B Leukemia and Antagonizes mTOR Inhibitors, Suggesting a Role for Interleukin-7R1± Signaling. <i>Cancer Research</i> , 2007, 67, 9963-9970.	0.4	64
188	In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. <i>Blood</i> , 2007, 109, 2008-2013.	0.6	42
189	Use of Rituximab in Conjunction With Immunosuppressive Chemotherapy as a Novel Therapy for Epstein Barr Virus-associated Hemophagocytic Lymphohistiocytosis. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 569-573.	0.3	103
190	A Phase I Trial of Sirolimus (Rapamycin) in Pediatric Patients with Relapsed/Refractory Leukemia.. <i>Blood</i> , 2007, 110, 2834-2834.	0.6	7
191	The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. <i>Blood</i> , 2006, 107, 1149-1155.	0.6	165
192	Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). <i>Blood</i> , 2006, 108, 1965-1971.	0.6	82
193	In Vivo Control of Acute Lymphoblastic Leukemia by Immunostimulatory CpG Oligonucleotides.. <i>Blood</i> , 2006, 108, 1868-1868.	0.6	15
194	Development of Cold Agglutinin Autoimmune Hemolytic Anemia During Treatment for Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 397-399.	0.3	15
195	Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). <i>Blood</i> , 2005, 105, 2443-2448.	0.6	151
196	Murine Ultrasonography Confirms That Rapamycin Is Effective Against Autoimmune Lymphoproliferative Syndrome (ALPS).. <i>Blood</i> , 2005, 106, 2386-2386.	0.6	1
197	Cell Division Rates of Primary Human Precursor B Cells in Culture Reflect In Vivo Rates. <i>Stem Cells</i> , 2004, 22, 1111-1120.	1.4	39
198	IL-7 and Thymic Stromal Lymphopoietin (TSLP) Stimulate Proliferation of All Cells and Reverse mTOR Inhibitor-Induced Growth Inhibition, Suggesting a Role for IL-7R1± Signaling in All.. <i>Blood</i> , 2004, 104, 1893-1893.	0.6	0

#	ARTICLE	IF	CITATIONS
199	mTOR Inhibitors Induce Apoptosis and Inhibit Growth of Primary Adult Human ALL in Xenograft and Tissue Culture Models.. Blood, 2004, 104, 2748-2748.	0.6	0
200	The gamma-Globin Promoter Has a Major Role in Competitive Inhibition of beta-Globin Gene Expression in Early Erythroid Development. DNA and Cell Biology, 1999, 18, 293-303.	0.9	9